The Rich countries have already guaranteed more than 1 billion doses of coronavirus vaccines, which arouses concern that the rest of the world will be at the end of the row of the global effort to defeat the pathogen.
The United States and the United Kingdom closed agreements for supplies of Sanofi and his partner GlaxoSmithKlineas well as with Japan and Pfizer. The European Union it has also acted quickly to obtain vaccines, long before they confirm if it will work.
While international groups and various nations promise to make vaccines affordable and accessible to all, doses will hardly meet demand for a global population of 7.8 billion people. The possibility of richer countries monopolizing supply, a scenario that developed in the swine flu pandemic 2009, has fueled the concerns of poor nations and health advocates.
Until now, The United States, Great Britain, the European Union and Japan have secured close to 1.3 billion doses of possible vaccines against Covid, according to the signature of Airfinity analysis, based in London. Options for more supplies or pending offers would add about 1.5 billion doses to that total, the figures show.
The row for favorite vaccines
“Although there is an optimistic assessment of scientific progress, there are still not enough vaccines for the world,” according to Rasmus Bech Hansen, Executive Director of Airfinity. What’s also important to note is that most vaccines may require two doses, she said.
Some favorites, such as the U. of Oxford and its partner AstraZeneca and a collaboration Pfizer-BioNTech SEThey are already in final-stage studies, raising hopes that there will soon be a weapon to fight Covid. But developers still have to overcome a number of obstacles: demonstrate that your vaccines are effective, gain approval, and increase manufacturing. Global supply could reach 1 billion doses through the first quarter of 2022, Airfinity predicts.
The World Health Organization (WHO), the Coalition for Outbreak Preparedness Innovations and the Global Alliance for Vaccines and Immunization, known as GAVI, are working together to achieve equitable and wide access. They outlined a $ 18 billion plan in June to develop vaccines and guarantee 2 billion doses by the end of 2021..
The initiative, known as Covax, aims to give governments the opportunity to hedge the risk of unsuccessfully supporting vaccines and offering other nations with limited resources access to doses that would otherwise be unaffordable.
In June, AstraZeneca became the first manufacturer to be part of the GAVI program, promising 300 million doses. Pfizer and BioNTech signaled interest in supplying vaccines to Covax.
Brazil, the country with the second highest number of coronavirus cases, It also reached an agreement to guarantee doses of the Oxford-AstraZeneca vaccine.